|Application ||WB, IHC-P, E|
|Other Accession||AAI09386, 14211875|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||9232 Da|
|Application Notes||ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL.|
|Target/Specificity||SPINK7; ECRG2 antibody is predicted to not cross-react with other ECRG family members|
|Reconstitution & Storage||ECRG2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||ECRG2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Probable serine protease inhibitor.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.
Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem. Biophys. Res. Commun. 2003; 302:904-15.
Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 2007; 28:2274-81
Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J. Biol. Chem. 2009; 284:30897-906
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.